Cargando…
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial
Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478738/ https://www.ncbi.nlm.nih.gov/pubmed/32558897 http://dx.doi.org/10.1084/jem.20191712 |
_version_ | 1783580120511938560 |
---|---|
author | Frank, Matthew J. Khodadoust, Michael S. Czerwinski, Debra K. Haabeth, Ole A.W. Chu, Michael P. Miklos, David B. Advani, Ranjana H. Alizadeh, Ash A. Gupta, Neel K. Maeda, Lauren S. Reddy, Sunil A. Laport, Ginna G. Meyer, Everett H. Negrin, Robert S. Rezvani, Andrew R. Weng, Wen-Kai Sheehan, Kevin Faham, Malek Okada, Ami Moore, A. Holliston Phillips, Destiny L. Wapnir, Irene L. Brody, Joshua D. Levy, Ronald |
author_facet | Frank, Matthew J. Khodadoust, Michael S. Czerwinski, Debra K. Haabeth, Ole A.W. Chu, Michael P. Miklos, David B. Advani, Ranjana H. Alizadeh, Ash A. Gupta, Neel K. Maeda, Lauren S. Reddy, Sunil A. Laport, Ginna G. Meyer, Everett H. Negrin, Robert S. Rezvani, Andrew R. Weng, Wen-Kai Sheehan, Kevin Faham, Malek Okada, Ami Moore, A. Holliston Phillips, Destiny L. Wapnir, Irene L. Brody, Joshua D. Levy, Ronald |
author_sort | Frank, Matthew J. |
collection | PubMed |
description | Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89%) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40% of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe. |
format | Online Article Text |
id | pubmed-7478738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-74787382021-03-07 Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial Frank, Matthew J. Khodadoust, Michael S. Czerwinski, Debra K. Haabeth, Ole A.W. Chu, Michael P. Miklos, David B. Advani, Ranjana H. Alizadeh, Ash A. Gupta, Neel K. Maeda, Lauren S. Reddy, Sunil A. Laport, Ginna G. Meyer, Everett H. Negrin, Robert S. Rezvani, Andrew R. Weng, Wen-Kai Sheehan, Kevin Faham, Malek Okada, Ami Moore, A. Holliston Phillips, Destiny L. Wapnir, Irene L. Brody, Joshua D. Levy, Ronald J Exp Med Article Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89%) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40% of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe. Rockefeller University Press 2020-06-19 /pmc/articles/PMC7478738/ /pubmed/32558897 http://dx.doi.org/10.1084/jem.20191712 Text en © 2020 Frank et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Frank, Matthew J. Khodadoust, Michael S. Czerwinski, Debra K. Haabeth, Ole A.W. Chu, Michael P. Miklos, David B. Advani, Ranjana H. Alizadeh, Ash A. Gupta, Neel K. Maeda, Lauren S. Reddy, Sunil A. Laport, Ginna G. Meyer, Everett H. Negrin, Robert S. Rezvani, Andrew R. Weng, Wen-Kai Sheehan, Kevin Faham, Malek Okada, Ami Moore, A. Holliston Phillips, Destiny L. Wapnir, Irene L. Brody, Joshua D. Levy, Ronald Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial |
title | Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial |
title_full | Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial |
title_fullStr | Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial |
title_full_unstemmed | Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial |
title_short | Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial |
title_sort | autologous tumor cell vaccine induces antitumor t cell immune responses in patients with mantle cell lymphoma: a phase i/ii trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478738/ https://www.ncbi.nlm.nih.gov/pubmed/32558897 http://dx.doi.org/10.1084/jem.20191712 |
work_keys_str_mv | AT frankmatthewj autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT khodadoustmichaels autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT czerwinskidebrak autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT haabetholeaw autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT chumichaelp autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT miklosdavidb autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT advaniranjanah autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT alizadehasha autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT guptaneelk autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT maedalaurens autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT reddysunila autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT laportginnag autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT meyereveretth autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT negrinroberts autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT rezvaniandrewr autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT wengwenkai autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT sheehankevin autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT fahammalek autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT okadaami autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT mooreaholliston autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT phillipsdestinyl autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT wapnirirenel autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT brodyjoshuad autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial AT levyronald autologoustumorcellvaccineinducesantitumortcellimmuneresponsesinpatientswithmantlecelllymphomaaphaseiiitrial |